Publications

Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. by Sader HS, Rhomberg PR, Farrell DJ and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 379-381.

Initial broth microdilution quality control guidelines for Debio 1452, a FabI inhibitor antimicrobial agent. by Ross JE, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (11): 7151-7152

Analysis of vancomycin susceptibility testing results for presumptive categorization of telavancin. by Mendes RE, Farrell DJ, Flamm RK, Sader HS and Jones RN published in J. Clin. Microbiol. 2015; 53 (8): 2727-2730

Microbiological assessment of polymyxin B components tested alone and in combination. by Kassamali Z, Prince RA, Danziger LH, Rotschafer JC, Rhomberg PR and Jones RN published in Antimicrob. Agents. Chemother. 2015; 59 (12): 7823-7825

Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Global. Antimicrob. Res. 2015; 3: 161-165

Validation of Sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination. by Jones RN, Holliday NM and Krause KM published in Antimicrob. Agents Chemother. 2015; 59 (8): 5036-5039,

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. by Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G and Newman JV published in Sci. Rep. 2015; 5: 11827

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin. by Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 73-77

Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. by Rose HR, Holzman RS, Altman DR, Smyth DS, Wasserman GA, Kafer JM, Wible M, Mendes RE, Torres VJ and Shopsin B published in J. Infect. Dis. 2015; 211 (12): 1862-1874

Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. by Stryjewski ME, Jones RN and Corey GR published in Diagn. Microbiol. Infect. Dis. 2015; 81 (3): 183-188

Validation of a commercial dry-form broth microdilution device (Sensititre®) for testing tedizolid, a new oxazolidinone. by Jones RN, Holliday NM and Rhomberg PR published in J. Clin. Microbiol. 2015; 53 (2): 657-659

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying the revised susceptibility testing method. by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (1): 702-706

Multilocus sequence typing of Mycobacterium xenopi. by Alexander DC, Marras TK, Ma JH, Mirza S, Liu D, Kus JV, Soualhine H, Escuyer V, Warshauer D, Brode SK, Farrell DJ and Jamieson FB published in J. Clin. Microbiol. 2014; 52 (11): 3973-3977

Quality control MIC ranges for telavancin with application of a revised CLSI reference broth microdilution method. by Ross JE, Mendes RE and Jones RN published in J. Clin. Microbiol. 2014; 52 (9): 3399-3401

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. by Dallow J, Otterson LG, Huband MD, Krause KM and Nichols WW published in Int. J. Antimicrob. Agents. 2014; 44 (6): 552-556

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective. by Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP and Lahiri SD published in J. Antimicrob. Chemother. 2014; 69 (8): 2065-2075

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease. by Barriere SL, Farrell DJ, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (4): 327-329

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 323-327

Avibactam reverts the ceftazidime MIC₉₀ of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. by Flamm RK, Stone GG, Sader HS, Jones RN and Nichols WW published in J. Chemother. 2014; 26 (6): 333-338

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. by Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J and Turnidge J published in Antimicrob. Agents Chemother. 2014; 58 (4): 2006-2012

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. by VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents Chemother. 2014; 58 (10): 6024-6031

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. by Mendes RE, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1579-1581

Daptomycin activity when tested against 164,457 bacterial isolates from hospitalized patients: Summary of 8 years of a worldwide surveillance programme (2005-2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (5): 465-469

Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2434-2437

Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. by Ross JE, Scangarella-Oman NE, Flamm RK and Jones RN published in J. Clin. Microbiol. 2014; 52 (7): 2629-2632

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria. by Pfaller MA, Messer SA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (1): 108-114

Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria. by Pfaller MA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (9): 3223-3229

Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). by Pfaller MA, Flamm RK, Sader HS and Jones RN published in Diag. Microbiol. Infect. Dis 2014; 78 (4): 422-428

Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. by Pfaller MA, Castanheira M, Messer SA, Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 79 (2): 198-204

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. by Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR and Martin-Mazuelos published in Antimicrob. Agents Chemother. 2014; 58 (2): 916-922

Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens. by Montgomery AB, Rhomberg PR, Abuan T, Walters KA and Flamm RK published in Antimicrob. Agents Chemother. 2014; 58 (7): 3714-3719

Contemporary diversity of ß-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent ß-lactamase groups. by Castanheira M, Farrell SE, Krause KM, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2014; 58 (2): 833-838

Amikacin/fosfomycin (5:2 ratio): characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics. by Montgomery AB, Rhomberg PR, Abuan T, Walters KA and Flamm RK published in Antimicrob. Agents Chemother. 2014; 58 (7): 3708-3713

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. by Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (1): 19-25

Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin. by Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L and McNutt LA published in J. Antimicrob. Chemother. 2014; 69 (9): 2547-2555

Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians! by Jones RN, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 80 (1): 91-92

Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies. by Farrell DJ, Mendes RE, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (9): 5547-5551

Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. by Marchand-Austin A, Rawte P, Toye B, Jamieson FB, Farrell DJ and Patel SN published in Anaerobe. 2014; 28: 120-125

Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying ß-lactamases prevalent in the United States. by Castanheira M, Williams G, Jones RN and Sader HS published in Microb. Drug Res. 2014; 20 (5): 436-440

Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae testing susceptible to cefepime by reference methods. by Picao RC, Jones RN, Mendes RE and Castanheira M published in J. Clin. Microbiol. 2013; 51 (7): 2388-2390

Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial. by Ross JE, Scangarella-Oman NE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 437-439

Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? by Farrell DJ published in J. Clin. Gastroenterol. 2013; 47 (3): 205-211

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species. by Jones RN, Flamm RK, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 89-93

Dissemination of a pSCFS3-like cfr-carrying plasmid in Staphylococcus aureus and Staphylococcus epidermidis clinical isolates recovered from hospitals in Ohio. by Mendes RE, Deshpande LM, Bonilla HF, Schwarz S, Huband MD, Jones RN and Quinn JP published in Antimicrob. Agents Chemother. 2013; 57 (7): 2923-2928

Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 217-221

Rapid detection of antibiotic-resistant organism carriage for infection prevention. by Diekema DJ and Pfaller MA published in Clin. Infect. Dis. 2013; 56 (11): 1614-1620

Comprehensive update of dalbavancin activity when tested against uncommonly isolated streptococci, Corynebacterium spp., Listeria monocytogenes and Micrococcus spp. (1,357 strains). by Jones RN and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 76 (2): 239-240

Comparative potencies of contemporary generic vancomycin lot: In-vitro assay results from nine products and a reference reagent-grade sample. by Jones RN, Watters AA, Flamm RK and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 76 (2): 237-238

10 x ’20 Progress–Development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America. by Boucher HW, Talbot GH, Benjamin DK, Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA and Gilbert D for the Infectious Diseases Society of America published in Clin. Infect. Dis. 2013; 56 (12): 1685-1694

An evaluation of vancomycin susceptibility testing for methicillin-resistant S. aureus: A comparison of Etest and three automated testing methods. by Rybak MJ, Vidaillac C, Sader H, Rhomberg P, Salimnia H, Briski L, Wanger A and Jones R published in J. Clin. Microbiol. 2013; 51 (7): 2077-2081